Last reviewed · How we verify
Euvichol-S Oral Cholera Vaccine
Euvichol-S Oral Cholera Vaccine is a Live attenuated oral vaccine Small molecule drug developed by Albert B. Sabin Vaccine Institute. It is currently FDA-approved for Prevention of cholera caused by Vibrio cholerae O1 and O139 in endemic and epidemic areas. Also known as: cholera: inactivated oral, Euvichol.
Euvichol-S is a live attenuated oral cholera vaccine that stimulates mucosal and systemic immune responses against Vibrio cholerae.
Euvichol-S is a live attenuated oral cholera vaccine that stimulates mucosal and systemic immune responses against Vibrio cholerae. Used for Prevention of cholera caused by Vibrio cholerae O1 and O139 in endemic and epidemic areas.
At a glance
| Generic name | Euvichol-S Oral Cholera Vaccine |
|---|---|
| Also known as | cholera: inactivated oral, Euvichol |
| Sponsor | Albert B. Sabin Vaccine Institute |
| Drug class | Live attenuated oral vaccine |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains live attenuated (weakened) strains of Vibrio cholerae O1 and O139 that replicate in the intestinal tract, triggering both local intestinal IgA antibody production and systemic immune responses. This mucosal immunization approach provides protection against cholera infection by preventing bacterial colonization and toxin-mediated disease in the small intestine.
Approved indications
- Prevention of cholera caused by Vibrio cholerae O1 and O139 in endemic and epidemic areas
Common side effects
- Abdominal discomfort or cramping
- Diarrhea
- Nausea
- Vomiting
- Fever
Key clinical trials
- Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya (PHASE4)
- Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Euvichol-S Oral Cholera Vaccine CI brief — competitive landscape report
- Euvichol-S Oral Cholera Vaccine updates RSS · CI watch RSS
- Albert B. Sabin Vaccine Institute portfolio CI
Frequently asked questions about Euvichol-S Oral Cholera Vaccine
What is Euvichol-S Oral Cholera Vaccine?
How does Euvichol-S Oral Cholera Vaccine work?
What is Euvichol-S Oral Cholera Vaccine used for?
Who makes Euvichol-S Oral Cholera Vaccine?
Is Euvichol-S Oral Cholera Vaccine also known as anything else?
What drug class is Euvichol-S Oral Cholera Vaccine in?
What development phase is Euvichol-S Oral Cholera Vaccine in?
What are the side effects of Euvichol-S Oral Cholera Vaccine?
Related
- Drug class: All Live attenuated oral vaccine drugs
- Manufacturer: Albert B. Sabin Vaccine Institute — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Immunology
- Indication: Drugs for Prevention of cholera caused by Vibrio cholerae O1 and O139 in endemic and epidemic areas
- Also known as: cholera: inactivated oral, Euvichol
- Compare: Euvichol-S Oral Cholera Vaccine vs similar drugs
- Pricing: Euvichol-S Oral Cholera Vaccine cost, discount & access